Topical brimonidine reduces IPL‐induced erythema without affecting efficacy: A randomized controlled trial in patients with facial telangiectasias
- 17 June 2018
- journal article
- research article
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 50 (10) , 1002-1009
Abstract
Background: Laser and intense pulsed light (IPL) are standard symptomatic treatments for superficial telangiectasias, but postoperative erythema, oedema, and pain may prolong downtime.Objectives: To investigate whether topical brimonidine reduces IPL‐induced inflammation in patients with moderate to severe facial telangiectasias.Methods: A randomized, two‐centre, single‐blinded, split‐face trial on adjuvant brimonidine and air‐cooling versus air‐cooling alone (control) in 19 patients treated in Denmark (n = 10 patients) and Belgium (n = 9). Brimonidine was applied to the allocated side after each of three facial IPL‐treatments, given at 3‐week intervals. Patients were assessed up to 1 month after the final treatment. Outcome measures included blinded clinical on‐site evaluation of erythema and oedema (5‐point‐scales), objective erythema‐scores (red‐filter analysis), patient‐evaluated pain (Visual Analogue Scale), IPL‐efficacy (blinded photo‐evaluation of telangiectasia clearance), and patient preference.Results: In total, 19 patients were enrolled and completed the study. IPL induced moderate to severe erythema after each treatment. Application of brimonidine, reduced erythema to baseline values compared to air‐cooling alone and sustained efficacy 24 hours after treatment (median difference reduction: score 1 at each assessment, P ≤ 0.022). Objective erythema‐scores supported clinical findings, demonstrating a median erythema reduction of 50–95% after application of brimonidine and air‐cooling compared to 9–28% reduction after air‐cooling alone (P ≥ 0.002). No difference in reduction of IPL‐induced oedema was observed between facial sides (P ≥ 0.227). Brimonidine and air‐cooling slightly and consistently reduced postoperative pain compared to air‐cooling alone (VAS 1.0 after brimonidine versus VAS 1.5–2.0 after air‐cooling alone at treatment 1–3, P ≤ 0.032). At 1‐month follow‐up, patients experienced excellent clearance of telangiectasias (75–100% clearance) on both facial sides (P = 1.000). Patient preference supported clinical data and 79% of patients preferred brimonidine to control (P = 0.019).Conclusion: Compared to air‐cooling alone, adjuvant brimonidine reduces IPL‐induced erythema and associated pain while maintaining a high IPL‐efficacy. Lasers Surg. Med. 50:1002–1009, 2018.Keywords
This publication has 34 references indexed in Scilit:
- Effect of Brimonidine on Retinal and Choroidal Neovascularization in a Mouse Model of Retinopathy of Prematurity and Laser-Treated RatsInvestigative Ophthalmology & Visual Science, 2011
- Lasers for vascular lesions: Standard guidelines of careIndian Journal of Dermatology, Venereology and Leprology, 2011
- Intense pulsed light vs. long-pulsed dye laser treatment of telangiectasia after radiotherapy for breast cancer: a randomized split-lesion trial of two different treatmentsBritish Journal of Dermatology, 2009
- Treatment of rosacea with intense pulsed light: significant improvement and long-lasting resultsBritish Journal of Dermatology, 2008
- Efficacy and cosmetic results of contact gel cooling of the skin during non‐ablative laser proceduresJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
- Adverse events associated with nonablative cutaneous visible and infrared laser treatmentJournal of the American Academy of Dermatology, 2006
- Treatment of superficial cutaneous vascular lesions: experience with the KTP 532 nm laserLasers in Medical Science, 2004
- Clinically Significant Facial Edema After Extensive Treatment With Purpura-Free Pulsed-Dye LaserDermatologic Surgery, 2003
- Treatment of telangiectasia: A reviewJournal of the American Academy of Dermatology, 1987
- Selective Photothermolysis: Precise Microsurgery by Selective Absorption of Pulsed RadiationScience, 1983